<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Allergic reactions to local anesthetics</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Allergic reactions to local anesthetics</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Allergic reactions to local anesthetics</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Schatz, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N Franklin Adkinson, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Local anesthetics (LAs) have been used to provide anesthesia since the initial use of cocaine in 1884 [<a href="#rid1">1</a>]. They may be administered by topical, infiltrative, nerve block, epidural, or spinal routes [<a href="#rid1">1</a>]. Adverse reactions to LAs are not uncommon, and most are nonallergic in etiology. However, allergic reactions to LAs can occur, and the evaluation and management of patients with these reactions will be reviewed here. Anaphylaxis in the setting of anesthesia or surgery is found separately. (See  <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2081.html" rel="external">"Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions"</a>.)</p><p>The use of LAs for infiltrative anesthesia and for topical anesthesia and a general approach to the management of pain and sedation in children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics"</a> and  <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">"Clinical use of topical anesthetics in children"</a> and  <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">"Procedural sedation in children: Approach"</a>.)</p><p class="headingAnchor" id="H4877755"><span class="h1">TYPES OF ALLERGIC REACTIONS TO LOCAL ANESTHETICS</span><span class="headingEndMark"> — </span>Two distinct types of allergic reactions to LAs have been described:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allergic contact dermatitis and delayed swelling at the site of administration</strong> – These types of reactions are uncommon but well established. They begin hours after injection and usually peak within 72 hours. (See <a class="local">'Rare: Delayed reactions (contact dermatitis or local swelling)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized urticaria and/or anaphylaxis</strong> – These types of reaction are rare, and the data implicating LAs are limited to case reports. Signs and symptoms begin quickly (within seconds to one hour) after injection, and this type of reaction is also called immediate hypersensitivity. Some immediate reactions may be immunoglobulin E (IgE) mediated. (See <a class="local">'Rare: Immediate reactions (urticaria and anaphylaxis)'</a> below.)</p><p></p><p class="headingAnchor" id="H1132592630"><span class="h1">MANAGEMENT ALGORITHM FOR NONALLERGY CLINICIANS</span><span class="headingEndMark"> — </span>Clinicians preparing to perform a procedure who encounter patients reporting past adverse reactions to LAs must determine if the history suggests a nonallergic reaction (common) or some type of allergic reaction, either delayed or immediate, both of which are rare. A decision algorithm for this situation is provided (<a class="graphic graphic_algorithm graphicRef117594" href="/z/d/graphic/117594.html" rel="external">algorithm 1</a>).</p><p>Nonallergic symptoms can arise from absorption or accidental intravenous injection of <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> or the LA, vasovagal reactions, or anxiety-related symptoms. The clinical manifestations of nonallergic reactions can resemble aspects of immediate allergic reactions. For example, dyspnea, hypotension, lightheadedness, and syncope are signs and symptoms that can be seen in both allergic and nonallergic reactions. However, certain symptoms can help distinguish between the two types. Immediate-type allergic reactions often include itching, urticaria, angioedema, or wheezing, and the absence of these symptoms suggests a nonallergic reaction.</p><p>Delayed-type allergic reactions, which generally present as contact dermatitis or local swelling at the injection site, are caused by a mechanism separate from immediate allergic reactions. Delayed-type allergy does not progress to anaphylaxis and is not dangerous. In contrast, immediate allergic reactions may be life threatening. If an immediate allergic reaction is suspected, the clinician must then decide how to manage the current scenario, depending upon whether the procedure is urgent or elective:</p><p class="bulletIndent1"><span class="glyph">●</span>If the procedure must go forward and the LA associated with the past reaction is known, the clinician can simply choose a different LA. The most useful and appropriate alternative LA for that procedure should be chosen. The clinician does not need to limit choices based on the chemical class of the LAs (amides versus esters) in question. This issue is discussed below. (See <a class="local">'Cross-reactivity'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the procedure must go forward and the culprit LA is not known, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> is a reasonable choice because it is among the most commonly used LAs, and, despite this, there are few reports of proven immediate allergy. Lidocaine can, however, cause delayed local swelling and contact allergy, but these reactions are not dangerous [<a href="#rid2">2</a>]. Alternatively, LAs can be avoided altogether.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the procedure is elective, the patient should be referred to an allergist or dermatologist, depending on the type of reaction, for further evaluation.</p><p></p><p class="headingAnchor" id="H2237581177"><span class="h2">Referral</span><span class="headingEndMark"> — </span>Suspected allergic reactions to LAs should be referred for evaluation when possible because most patients can tolerate some LA agents. Simply advising a patient to avoid all LAs is unnecessarily restrictive and subjects that patient either to the pain of procedures performed without local anesthesia or to the increased risks of general anesthesia.</p><p>Patients with contact dermatitis or delayed local swelling may be referred to either dermatology or allergy specialists who perform patch testing. Patients with suspected anaphylaxis should be referred to allergy specialists. Even patients whose reactions were more suggestive of sympathetic stimulation can benefit from allergy testing and challenge as the experience of having negative test results and tolerating a dose of an LA under close supervision is often sufficient to reduce the patient's anxiety about future use of LAs.</p><p class="headingAnchor" id="H2297330153"><span class="h1">COMMON: NONALLERGIC REACTIONS</span><span class="headingEndMark"> — </span>Nonallergic reactions to LAs are far more common than true allergic reactions. These reactions include sympathetic stimulation, psychomotor or anxiety-related reactions, vasovagal syncope, and systemic toxic effects related to the pharmacologic properties of these agents.</p><p class="headingAnchor" id="H2250917913"><span class="h2">Sympathetic stimulation</span><span class="headingEndMark"> — </span>Tachycardia, hypertension, anxiety, and palpitations may be caused by the release of endogenous catecholamines in response to pain. In addition, the vasoconstrictor <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> is sometimes added to LA solutions for the purposes of reducing bleeding, potentiating the degree of local anesthesia achieved, limiting the total dose required, and minimizing systemic absorption of the LA [<a href="#rid3">3,4</a>]. The amount of epinephrine in these preparations is too small to induce significant systemic responses in most normal subjects, as well as in those with heart disease, high blood pressure, hyperthyroidism, or on tricyclic antidepressants [<a href="#rid3">3-5</a>]. However, it is still possible that some patients are very sensitive to epinephrine's actions.</p><p class="headingAnchor" id="H3308342195"><span class="h2">Psychomotor reactions</span><span class="headingEndMark"> — </span>Psychomotor reactions or anxiety-related symptoms include hyperventilation (manifested by dyspnea and tachypnea), paresthesias in the fingers or perioral area, dizziness, palpitations, tachycardia, nausea, or simply "not feeling good" [<a href="#rid6">6,7</a>]. Note that these symptoms overlap with those of early LA toxicity. (See <a class="local">'Systemic toxic effects'</a> below.)</p><p class="headingAnchor" id="H3745890402"><span class="h2">Vasovagal syncope</span><span class="headingEndMark"> — </span>Vasovagal syncope is usually associated with bradycardia (rather than tachycardia) and pallor (rather than flushing). These differences can be helpful in distinguishing it from anaphylaxis. Rapid spontaneous recovery is also a common feature.</p><p class="headingAnchor" id="H3854040867"><span class="h2">Systemic toxic effects</span><span class="headingEndMark"> — </span>LAs can cause central nervous stimulation, even at therapeutic levels, and patients differ in their sensitivity to these effects. Highly sensitive individuals may experience circumoral numbness/tingling, anxiety, tremulousness, excitement, or even convulsions. At toxic doses, vasomotor collapse with hypotension, apnea, stupor, and myocardial dysfunction may occur. (See  <a class="medical medical_review" href="/z/d/html/14929.html" rel="external">"Clinical use of local anesthetics in anesthesia", section on 'Neurotoxicity of local anesthetics'</a>.)</p><p>One of the newer agents, articaine, has been implicated in the development of persistent paresthesias due to nerve damage [<a href="#rid8">8</a>]. The toxic effects of specific LAs are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6324.html" rel="external">"Subcutaneous infiltration of local anesthetics"</a> and  <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">"Clinical use of topical anesthetics in children"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">RARE: DELAYED REACTIONS (CONTACT DERMATITIS OR LOCAL SWELLING)</span><span class="headingEndMark"> — </span>LAs can cause delayed swelling, localized dermatitis, or mucosal inflammation at the site of administration due to delayed-type (type IV) hypersensitivity (<a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">table 1</a>) [<a href="#rid9">9-15</a>]. (See  <a class="medical medical_review" href="/z/d/html/13655.html" rel="external">"Clinical features and diagnosis of allergic contact dermatitis"</a> and  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis", section on 'Anesthetics'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Acute allergic contact dermatitis typically presents as a localized eczematous and pruritic rash appearing within 72 hours at the site of administration. Vesiculation, blistering, or weeping can occur. The area affected is limited to tissue that was in direct contact with the causal agent. LAs may also cause delayed-onset swelling, with or without overlying dermatitis, at sites of injection. Mucosal reactions may blister and progress to sloughing [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Evaluation usually consists of clinical history, patch testing, and possibly, challenge.</p><p class="headingAnchor" id="H6"><span class="h3">History</span><span class="headingEndMark"> — </span>The clinician should review the medical procedure in detail and events immediately surrounding it for possible exposure to other contact allergens, such as topical antibiotics [<a href="#rid16">16,17</a>], suture materials [<a href="#rid14">14</a>], rubber chemicals, or disinfectants [<a href="#rid18">18</a>].</p><p>Patients should be asked about prior reactions to LAs used in medical procedures and in over-the-counter products (preparations for hemorrhoids, vaginal irritation, sunburn, and other uses) [<a href="#rid9">9,19,20</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Other possible culprits</span><span class="headingEndMark"> — </span>The differential diagnosis of localized swelling and/or dermatitis at the site of an LA injection includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Excessive swelling due to operative trauma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local toxic effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergic contact dermatitis from other topical preparations, such as <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a>, disinfectants (eg, <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>), and other topical agents used in wound dressings [<a href="#rid18">18,21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergic contact dermatitis to additives and preservatives in the LA itself, such as sulfites and parabens, although these are believed to be relatively uncommon culprits [<a href="#rid23">23-29</a>].</p><p></p><p class="bulletIndent1">LA preparations may contain sulfite (bisulfite or metabisulfite), which are included to stabilize added vasoconstrictors. A small number of case reports have described local reactions attributed to sulfite sensitivity [<a href="#rid23">23-25</a>]. One case described a woman with severe edema of the face and neck after receiving an LA for dental work with a positive patch test to both the LA and metabisulfite [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">People with asthma that is exacerbated by sulfite in foods are not known to be at increased risk for reactions to sulfites in LAs. One study found that doses of metabisulfite of up to 10 times the amount usually found in LA preparations did not cause symptoms when injected subcutaneously in a group of patients with known sulfite-sensitive asthma [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Parabens (either methyl- or propyl-) are added to many commercial preparations of LAs as preservatives [<a href="#rid27">27</a>]. Parabens are an uncommon cause of contact dermatitis [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/z/d/html/13656.html" rel="external">"Common allergens in allergic contact dermatitis", section on 'Parabens'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h3">Patch testing</span><span class="headingEndMark"> — </span>Patch testing is a means of diagnosing type IV hypersensitivity reactions by exposing a small area of skin (usually the upper back) to the suspected allergen in a controlled manner. Patches are removed at 48 hours, and readings are usually taken at 48 and 72 hours [<a href="#rid9">9,30</a>]. A positive result varies from mild erythema and induration to severe vesiculation. The patient should not have applied a topical corticosteroid to the tested skin for at least one week and should not have taken systemic glucocorticoids for at least one to two weeks prior to testing [<a href="#rid31">31</a>]. Testing can be performed using aluminum or synthetic material chambers mounted on nonocclusive tape strips [<a href="#rid9">9</a>]. Techniques and material for patch testing are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">"Patch testing"</a>.)</p><p></p><p>The optimal concentration of LAs for use in patch testing has not been determined. In published studies, concentrations of <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> (in a petroleum vehicle) used for testing have ranged from 5 to 15 percent [<a href="#rid10">10,13,14,32,33</a>].</p><p class="headingAnchor" id="H4145293432"><span class="h3">Cross-reactivity</span><span class="headingEndMark"> — </span>LAs have been divided into two groups based upon their chemical structure (<a class="graphic graphic_table graphicRef57120" href="/z/d/graphic/57120.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group I</strong> – The benzoic acid ester agents, including <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">benzocaine</a>, procaine, and <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">tetracaine</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Group II</strong> – The amide agents, including <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, and <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a></p><p></p><p>Information about cross-reactivity among LAs based upon patch testing is limited. There is some evidence for cross-reactivity within each group of agents [<a href="#rid34">34-36</a>] and minimal evidence for cross-reactivity between the two groups [<a href="#rid34">34</a>]. Thus, we suggest choosing one or more drugs from the other LA group as an alternative agent for patch testing if that drug is useful for the patient's anticipated future needs. A case report described a patient with delayed hypersensitivity to several amide LAs (<a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a>, and <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>), which all contain a meta-xylene entity but not to articaine, which is a thiophene derivative (ie, not an ester or amide). The authors hypothesized that the meta-xylene entity could be the eliciting epitope in amide LA allergy and that, in such cases, articaine could be an alternative [<a href="#rid37">37</a>]. However, a subsequent report described a patient with delayed-type hypersensitivity to articaine with cross-reactivity with bupivacaine and lidocaine but tolerance of mepivacaine [<a href="#rid38">38</a>].</p><p>The commercially available standard T.R.U.E. TEST panel includes a "caine mix," which contains <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">tetracaine</a> hydrochloride, <a class="drug drug_general" data-topicid="8894" href="/z/d/drug information/8894.html" rel="external">dibucaine</a> hydrochloride, and <a class="drug drug_general" data-topicid="9092" href="/z/d/drug information/9092.html" rel="external">benzocaine</a>, representing both groups I and II LAs [<a href="#rid39">39</a>]. However, the clinician should consider whether the information provided by a positive test to this mix of LAs would be useful to the patient's care. In North America, dibucaine and benzocaine are used in topical and over-the-counter preparations, and tetracaine is used for spinal and ophthalmic anesthesia in some circumstances, but none of these agents are commonly used in dental, regional, or infiltration anesthesia. Thus, patch testing with individual LAs may be more helpful.</p><p class="headingAnchor" id="H9"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>A clinical history consistent with a delayed cutaneous reaction to an LA combined with a positive patch test result is sufficient for diagnosis.</p><p class="headingAnchor" id="H10"><span class="h2">Management</span><span class="headingEndMark"> — </span>Patients who have demonstrated type IV allergic reactions to one LA may tolerate other LAs. Management consists of identifying other agents that the patient tolerates. When evaluating patients for tolerance to other LAs, we suggest choosing an agent from the other chemical group (<a class="graphic graphic_table graphicRef57120" href="/z/d/graphic/57120.html" rel="external">table 2</a>). (See <a class="local">'Cross-reactivity'</a> above.)</p><p class="headingAnchor" id="H12"><span class="h1">RARE: IMMEDIATE REACTIONS (URTICARIA AND ANAPHYLAXIS)</span><span class="headingEndMark"> — </span>LAs have been implicated in rare, IgE-mediated, type I hypersensitivity reactions (<a class="graphic graphic_table graphicRef80466" href="/z/d/graphic/80466.html" rel="external">table 1</a>). These are also called immediate hypersensitivity reactions.</p><p class="headingAnchor" id="H1872574599"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Immediate hypersensitivity reactions to LAs are extremely rare. Evidence for their existence consists of a small number of case reports in which patients had reactions that were consistent with immediate hypersensitivity and positive skin tests were demonstrated [<a href="#rid40">40-50</a>].</p><p>The rarity of immediate hypersensitivity to LAs was demonstrated by two large series:</p><p class="bulletIndent1"><span class="glyph">●</span>One series included 162 patients who were evaluated over 10 years in the Danish Anaesthesia Allergy Center for suspected allergy associated with anesthesia and surgery [<a href="#rid51">51</a>]. No instances of true immediate hypersensitivity were identified. Skin testing to LAs was performed in all patients, and subcutaneous provocation (challenge) was performed regardless of skin testing results. In total, 162 patients underwent 203 provocations to various LAs, all of which were negative. Other culprit agents that were implicated included <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>, <a class="drug drug_general" data-topicid="9230" href="/z/d/drug information/9230.html" rel="external">cefuroxime</a>, and patent blue dye.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second series described 402 patients evaluated over 20 years in a German allergy clinic for reactions to LAs occurring within 30 minutes of injection [<a href="#rid52">52</a>]. Most occurred during outpatient dental or surgical procedures. Two patients (0.5 percent) were found to have true immediate allergy and positive intradermal skin tests to LAs. Acute urticaria (with or without angioedema) was the presenting symptom in 29 patients, of whom 14 were determined to have spontaneous urticaria, and 13 had reactions to other agents, including nonsteroidal antiinflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">atracurium</a>, cephalosporins, latex, gelatin, and dipyrone. All of these 27 patients had negative LA skin tests and nonreactive subcutaneous challenges, indicating the very high negative predictive value of skin testing.</p><p></p><p class="headingAnchor" id="H4098343079"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Clinical manifestations of immediate allergic reactions to LAs include pruritus, urticaria, bronchospasm, angioedema, rhinitis, laryngeal edema, and/or anaphylaxis, typically occurring <strong>within one hour</strong> of administration (<a class="graphic graphic_table graphicRef100732" href="/z/d/graphic/100732.html" rel="external">table 3</a>) [<a href="#rid40">40,41,43-50</a>]. A study of 100 dentists with histories of adverse reactions to <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> reported that the 13 individuals with documented immediate allergy based on lidocaine skin tests were significantly more likely to have experienced rhinitis, urticaria, and angioedema than those with negative immediate lidocaine skin tests [<a href="#rid53">53</a>]. Contact urticaria to topical creams containing LAs (eg, lidocaine, <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">prilocaine</a>, and castor oil; EMLA cream [brand name]) has also been reported [<a href="#rid42">42</a>].</p><p>Case reports describe patients with reactions to <a class="drug drug_general" data-topicid="9610" href="/z/d/drug information/9610.html" rel="external">mepivacaine</a> and <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> [<a href="#rid40">40</a>], articaine [<a href="#rid41">41</a>], lidocaine [<a href="#rid43">43-46</a>], levobupivacaine and <a class="drug drug_general" data-topicid="9873" href="/z/d/drug information/9873.html" rel="external">ropivacaine</a> [<a href="#rid47">47</a>], mepivacaine, lidocaine, and <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a> [<a href="#rid48">48</a>], and epidural lidocaine and <a class="drug drug_general" data-topicid="9245" href="/z/d/drug information/9245.html" rel="external">chloroprocaine</a> [<a href="#rid49">49</a>]. Drug-specific IgE has been demonstrated in vitro in just one report (to mepivacaine) [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>Evaluation of a patient with a possible immediate allergic reaction following administration of an LA involves a detailed history, consideration of other possible allergens, skin testing, and challenge. The most common indication for skin testing and challenge is a history of symptoms that could have been either immediate allergy or nonallergic (such as syncope or hypotension).</p><p class="headingAnchor" id="H20"><span class="h3">History</span><span class="headingEndMark"> — </span>The clinician should review the entire procedure and events surrounding it. As much information as possible regarding the patient's reaction(s) should be obtained, including the specific drug preparation used, the presence of added vasoconstrictor or preservatives, the time between administration and onset of the reaction, and the specific symptoms experienced. Any documented objective records should be ascertained and reviewed.</p><p class="headingAnchor" id="H21"><span class="h3">Other potential allergens</span><span class="headingEndMark"> — </span>Other potential allergens often encountered during minor medical procedures include latex, disinfectants, antibiotics, and analgesics [<a href="#rid55">55,56</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Latex from gloves or other medical equipment used during procedures (especially dental procedures) can be a source of allergic reactions. However, the incidence of latex reactions has declined dramatically with the widespread use of latex-free products. (See  <a class="medical medical_review" href="/z/d/html/5543.html" rel="external">"Latex allergy: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">Chlorhexidine</a> is a topical antiseptic and surgical scrub that is increasingly implicated in anaphylaxis occurring during surgical and dental procedures [<a href="#rid57">57,58</a>]. Products containing chlorhexidine include antiseptic solutions applied to surgical fields (especially mucosal surfaces) and urethral lubricants. Chlorhexidine hypersensitivity is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Chlorhexidine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antibiotics, both topical and systemic, can act as allergens. Systemic antibiotics are a well-established source of anaphylactic reactions. Topical antibiotic preparations, including <a class="drug drug_general" data-topicid="9052" href="/z/d/drug information/9052.html" rel="external">bacitracin</a> and the combination of <a class="drug drug_general" data-topicid="9058" href="/z/d/drug information/9058.html" rel="external">bacitracin-neomycin-polymyxin b</a>, have also been implicated in anaphylaxis, particularly when applied to nonintact skin following minor procedures [<a href="#rid59">59-61</a>]. (See  <a class="medical medical_review" href="/z/d/html/2077.html" rel="external">"Perioperative anaphylaxis: Clinical manifestations, etiology, and management", section on 'Antibiotics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NSAIDs and opiates are both capable of causing anaphylaxis or reactions resembling it in susceptible patients [<a href="#rid62">62</a>]. Allergic reactions to NSAIDs are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/2082.html" rel="external">"NSAIDs (including aspirin): Allergic and pseudoallergic reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parabens (either methyl- or propyl-) are added to many preparations of commonly used LAs as a preservative [<a href="#rid27">27</a>]. Parabens are structurally related to the benzoic acid ester LAs and are capable of producing immediate hypersensitivity reactions [<a href="#rid63">63</a>]. In several case reports, the apparent adverse reaction to an LA was actually due to immediate hypersensitivity to paraben [<a href="#rid5">5,64-67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethylenediaminetetraacetic acid (EDTA) added to an LA as a preservative was implicated in one case of systemic allergic reactions to LAs [<a href="#rid68">68</a>]. The patient had also reacted to intravenous radiocontrast agents containing EDTA. Intradermal skin testing was positive to <a class="drug drug_general" data-topicid="9401" href="/z/d/drug information/9401.html" rel="external">calcium disodium EDTA</a> at a concentration of 0.3 mg/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depot corticosteroids and additives within these preparations are another potential cause of immediate allergy [<a href="#rid69">69,70</a>]. This is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/16379.html" rel="external">"Hypersensitivity reactions to systemic glucocorticoids"</a>.)</p><p></p><p class="headingAnchor" id="H22"><span class="h3">Skin testing and challenge</span><span class="headingEndMark"> — </span>Skin testing and subcutaneous challenge are performed to determine what alternative LAs the patient tolerates. In all of the case reports of immediate reactions, alternative anesthetics that the patients tolerated were identified in this manner [<a href="#rid40">40-49</a>].</p><p class="headingAnchor" id="H2365699408"><span class="h4">Reagents</span><span class="headingEndMark"> — </span>It is important to communicate with the referring clinician in order to include any LAs that are preferred or required for specific procedures. If the LA associated with the past reaction was not <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> or is <strong>unknown</strong>, lidocaine should be chosen for testing since it is commonly available and because there are cases of tolerance of lidocaine even in patients who reported previous reactions to lidocaine [<a href="#rid56">56,71</a>]. If lidocaine was the LA associated with prior reaction, the type of reaction and indication for the LA would help the clinician and patient decide whether to test with lidocaine or an alternate LA (<a class="graphic graphic_table graphicRef57120" href="/z/d/graphic/57120.html" rel="external">table 2</a>). In addition to the chosen LA, skin testing should include a positive (histamine) and negative (<a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>) control.</p><p>Preparations <strong>without vasoconstrictors</strong> (such as <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>) should be used for skin testing because the vasoconstrictor may mask a positive test [<a href="#rid72">72</a>].</p><p>Although paraben preservatives may occasionally be responsible for LA reactions, the wider availability of LA preparations containing parabens, as well as the infrequency of paraben reactions, suggests that initial skin tests may be performed with paraben-containing preparations. However, if skin testing is positive, paraben sensitivity must be considered. This can be evaluated by repeat testing with preservative-free preparations [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H3941385840"><span class="h4">Cross-reactivity</span><span class="headingEndMark"> — </span>Evidence for the relevance of the ester/amide groups (<a class="graphic graphic_table graphicRef57120" href="/z/d/graphic/57120.html" rel="external">table 2</a>) to immediate allergic reactions is limited to case reports, in which findings about cross-reactivity were inconsistent [<a href="#rid40">40,41,46-48</a>]. Therefore, the author and editors of this topic do not believe the evidence supports basing the choice of alternative LAs on the structural groups and that a better approach is to choose alternative LAs that are likely to be useful to the patient or referring provider in the future.</p><p class="headingAnchor" id="H669002"><span class="h4">Testing procedures</span><span class="headingEndMark"> — </span>There are several approaches to skin testing and challenge with LAs [<a href="#rid73">73,74</a>]. The approach described herein is that of the author and has proven clinically useful (<a class="graphic graphic_table graphicRef80642" href="/z/d/graphic/80642.html" rel="external">table 4</a>) [<a href="#rid75">75-78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin prick testing with undiluted drug is performed initially.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If prick testing is negative, intracutaneous (intradermal) testing should be performed with a 1:100 dilution of drug [<a href="#rid52">52</a>]. Undiluted group I drugs have been reported to yield positive intradermal tests in up to 20 percent of subjects with no history of an adverse LA reaction [<a href="#rid75">75</a>]. Use of 1:10 dilutions can also yield false-positive results [<a href="#rid52">52</a>], although some guidelines do include this concentration [<a href="#rid73">73,79</a>]. However, we advocate the use of a 1:100 dilution for intradermal testing since false-positive skin tests have not been reported with this concentration [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1">A general discussion of the techniques for allergen skin testing is provided elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">"Overview of skin testing for IgE-mediated allergic disease"</a>.)</p><p></p><p class="headingAnchor" id="H668976"><span class="h4">Skin test interpretation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positive result</strong> – For the purposes of management, a positive result should be interpreted as possible allergy, unless a normal control subject has reacted to the same solution.</p><p></p><p class="bulletIndent1">If a paraben-containing preparation was used for testing, paraben sensitivity should be considered. Testing should be repeated with a paraben-free solution (ie, from a single-dose vial). If the paraben-free preparation also elicits a positive test, then that specific LA should be avoided. Other LAs could then be evaluated looking for a safe alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Negative result</strong> – In the case of LAs (like almost all other drugs), skin testing with the native drug cannot be considered absolutely conclusive in excluding IgE-mediated allergy, since the allergenic determinant(s) or hapten-carrier complex responsible for IgE-mediated allergic reactions to LAs have not been identified. Despite this, case reports and extensive clinical experience suggest that a negative intradermal test is predictive of tolerance of that LA on challenge [<a href="#rid52">52,76,77</a>].</p><p></p><p class="bulletIndent1">False-negative skin tests have occurred in less than 1 percent of reported patients. These individuals reacted when challenged with a drug to which they were skin test negative [<a href="#rid75">75,80</a>]. However, these reactions were very mild and often were not suggestive of IgE-mediated reactions [<a href="#rid67">67,75,81</a>].</p><p></p><p class="bulletIndent1">If the prick and intradermal skin tests are negative, incremental challenge is performed next to confirm that the patient tolerates the drug in question.</p><p></p><p class="headingAnchor" id="H23"><span class="h4">Challenge</span><span class="headingEndMark"> — </span>A negative skin test to an LA should be confirmed with a subsequent incremental challenge before clinical use of that drug is recommended because false-negative skin tests are rare but possible [<a href="#rid80">80</a>].</p><p>Challenge should generally not be performed with a drug for which skin testing was positive at a dilution of 1:100 if the history was suggestive of an IgE-mediated reaction. However, one may consider challenge in spite of a positive skin test at this dilution if there are limited alternatives available or if the history was not consistent with an IgE-mediated reaction.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recommended protocol</strong> – Challenge procedures should be performed under careful observation, with experienced personnel and appropriate facilities immediately available to treat a potential adverse reaction. The patient is usually observed for at least one hour after the final challenge step.</p><p></p><p class="bulletIndent1">A widely used protocol for subcutaneous incremental challenge involves injections, typically in the upper lateral arm, of gradually increasing volumes of an LA to which the patient is skin test negative (<a class="graphic graphic_table graphicRef56788" href="/z/d/graphic/56788.html" rel="external">table 5</a>) [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A single-blind <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> step may be added (as the first step) in a patient whose prior reaction is strongly suspected of being anxiety related in origin [<a href="#rid75">75,81</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After a negative skin test and a negative single-blind <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> challenge, we sometimes omit the 0.1 mL and 0.5 mL undiluted subcutaneous challenge steps and proceed directly to a subcutaneous injection of 1 mL of undiluted LA [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – A challenge is considered positive if the patient develops any of the following within 20 minutes after administration of any challenge step: a wheal-and-flare reaction at the site of injection, any acute-onset rash distant from the site of challenge, a 15 percent decrease in blood pressure, wheezing, or a 15 percent decrease in pulmonary function [<a href="#rid67">67</a>].</p><p></p><p>If an LA was tolerated on incremental challenge, adverse reactions to the next clinical use of that agent are uncommon and not likely to be IgE mediated [<a href="#rid82">82-84</a>]. If the LA is tolerated on challenge but the past reaction was highly suggestive of true allergy, it is important to reconsider other possible allergens. (See <a class="local">'Other potential allergens'</a> above.)</p><p class="headingAnchor" id="H2112850129"><span class="h2">Communication of results for future local anesthetic use</span><span class="headingEndMark"> — </span>After a specific LA has been tolerated in an incremental challenge, a report should be supplied to the referring clinician or dentist that includes the following information:</p><p class="bulletIndent1"><span class="glyph">●</span>The specific LA tolerated in challenge</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Its vasoconstrictor, preservative/stabilizer content (or if a preservative-free preparation should be used)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The total dose tolerated during challenge (which is useful for patients with toxic reactions)</p><p></p><p>The patient should not be at increased risk for experiencing an immediate allergic reaction if preparations with the same LA and additives as those given in the challenge are used in future procedures.</p><p class="headingAnchor" id="H3958422713"><span class="h2">Desensitization</span><span class="headingEndMark"> — </span>A report describes a patient with bilateral central vein occlusion and subsequent retinal edema who required intraocular <a class="drug drug_general" data-topicid="10337" href="/z/d/drug information/10337.html" rel="external">ranibizumab</a> injections every five weeks with ocular LA pretreatment [<a href="#rid85">85</a>]. She developed immediate reactions to <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="10278" href="/z/d/drug information/10278.html" rel="external">tetracaine</a>, benoxinate, and <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">bupivacaine</a>. Because of the history of reactions to multiple ocular LAs and the morbidity of the disease, an ocular desensitization protocol to bupivacaine was successfully implemented with seven steps over two hours.</p><p class="headingAnchor" id="H26"><span class="h2">Patients with past nonallergic reactions</span><span class="headingEndMark"> — </span>Several strategies exist for the prevention of subsequent nonallergic reactions to LAs:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with past psychomotor reactions and sympathetic stimulation, anxiety may be reduced by reassurance of the benign nature of these reactions, empiric use of a different LA, and, if necessary, premedication with an anxiolytic. A placebo-controlled challenge may also be useful under these circumstances.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with toxic effects, the cumulative dose used in future procedures should be kept as low as possible.</p><p></p><p class="headingAnchor" id="H4076835672"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">"Society guideline links: Drug allergy and hypersensitivity"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Most reactions to local anesthetics are nonallergic</strong> – Most idiosyncratic reactions to local anesthetics (LAs) are nonallergic in nature. Common nonallergic reactions include sympathetic stimulation from pain, psychomotor responses related to anxiety, or toxic effects attributable to heightened sensitivity to known properties of the drug or added vasopressor. Several strategies are proposed for minimizing the recurrence of these reactions. (See <a class="local">'Common: Nonallergic reactions'</a> above and <a class="local">'Patients with past nonallergic reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>True hypersensitivity reactions are rare but may take several forms</strong> – Rarely, LAs cause true hypersensitivity reactions. Both immediate, type I hypersensitivity (eg, urticaria, anaphylaxis) and delayed, type IV hypersensitivity (eg, contact dermatitis, delayed local swelling) have been described. (See <a class="local">'Types of allergic reactions to local anesthetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management algorithm for urgent use</strong> – A management algorithm is provided for situations in which a procedure is needed urgently and the patient has a history of a past reaction but there is insufficient time for evaluation (<a class="graphic graphic_algorithm graphicRef117594" href="/z/d/graphic/117594.html" rel="external">algorithm 1</a>). (See <a class="local">'Management algorithm for nonallergy clinicians'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral</strong> <strong>for suspected allergic reactions</strong> – Patients with suspected allergic reactions to LAs should be referred for evaluation (by an allergist or dermatologist) because most do not truly have allergy to LAs. (See <a class="local">'Referral'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anaphylaxis and immediate allergic reactions, which typically begin within one hour of drug administration, have been convincingly attributed to LAs in only a small number of case reports. Allergists can perform skin testing and subcutaneous challenge to evaluate these reactions and identify safe alternative LAs. If testing with LA is negative in cases with allergic symptoms, other allergens with simultaneous exposure, such as disinfectants, antibiotics, and latex, should be considered. (See <a class="local">'Rare: Immediate reactions (urticaria and anaphylaxis)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Contact dermatitis and delayed-onset localized swelling are examples of type IV, delayed-type hypersensitivity reactions. Symptoms develop at the site of exposure, one to three days after drug administration, and are rarely dangerous. Dermatologists can perform patch testing in some cases. (See <a class="local">'Rare: Delayed reactions (contact dermatitis or local swelling)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Eggleston ST, Lush LW. Understanding allergic reactions to local anesthetics. Ann Pharmacother 1996; 30:851.</a></li><li><a class="nounderline abstract_t">To D, Kossintseva I, de Gannes G. Lidocaine contact allergy is becoming more prevalent. Dermatol Surg 2014; 40:1367.</a></li><li><a class="nounderline abstract_t">Cawson RA, Curson I, Whittington DR. The hazards of dental local anaesthetics. Br Dent J 1983; 154:253.</a></li><li><a class="nounderline abstract_t">Chernow B, Balestrieri F, Ferguson CD, et al. Local dental anesthesia with epinephrine. Minimal effects on the sympathetic nervous system or on hemodynamic variables. Arch Intern Med 1983; 143:2141.</a></li><li><a class="nounderline abstract_t">Latronica RJ, Goldberg AF, Wightman JR. Local anesthetic sensitivity. Report of a case. Oral Surg Oral Med Oral Pathol 1969; 28:439.</a></li><li><a class="nounderline abstract_t">Dower JS Jr. A review of paresthesia in association with administration of local anesthesia. Dent Today 2003; 22:64.</a></li><li><a class="nounderline abstract_t">Fiset L, Milgrom P, Weinstein P, et al. Psychophysiological responses to dental injections. J Am Dent Assoc 1985; 111:578.</a></li><li><a class="nounderline abstract_t">Wells JP, Beckett H. Articaine hydrochloride: a safe alternative to lignocaine? Dent Update 2008; 35:253.</a></li><li><a class="nounderline abstract_t">Melamed J, Beaucher WN. Delayed-type hypersensitivity (type IV) reactions in dental anesthesia. Allergy Asthma Proc 2007; 28:477.</a></li><li><a class="nounderline abstract_t">Weightman W, Turner T. Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature. Contact Dermatitis 1998; 39:265.</a></li><li><a class="nounderline abstract_t">García F, Iparraguirre A, Blanco J, et al. Contact dermatitis from prilocaine with cross-sensitivity to pramocaine and bupivacaine. Contact Dermatitis 2007; 56:120.</a></li><li><a class="nounderline abstract_t">Pérez-Pérez LC, Fernández-Redondo V, Ginarte-Val M, et al. Allergic contact dermatitis from EMLA cream in a hemodialyzed patient. Dermatitis 2006; 17:85.</a></li><li><a class="nounderline abstract_t">Mackley CL, Marks JG Jr, Anderson BE. Delayed-type hypersensitivity to lidocaine. Arch Dermatol 2003; 139:343.</a></li><li><a class="nounderline abstract_t">Amado A, Sood A, Taylor JS. Contact allergy to lidocaine: a report of sixteen cases. Dermatitis 2007; 18:215.</a></li><li><a class="nounderline abstract_t">Trautmann A, Stoevesandt J. Differential diagnosis of late-type reactions to injected local anaesthetics: Inflammation at the injection site is the only indicator of allergic hypersensitivity. Contact Dermatitis 2019; 80:118.</a></li><li><a class="nounderline abstract_t">Sood A, Taylor JS. Bacitracin: allergen of the year. Am J Contact Dermat 2003; 14:3.</a></li><li><a class="nounderline abstract_t">Grandinetti PJ, Fowler JF Jr. Simultaneous contact allergy to neomycin, bacitracin, and polymyxin. J Am Acad Dermatol 1990; 23:646.</a></li><li><a class="nounderline abstract_t">Opstrup MS, Johansen JD, Zachariae C, Garvey LH. Contact allergy to chlorhexidine in a tertiary dermatology clinic in Denmark. Contact Dermatitis 2016; 74:29.</a></li><li><a class="nounderline abstract_t">Connolly M, Mehta A, Sansom JE, Dunnill MG. Allergic contact dermatitis from tetracaine in the beauty industry. Contact Dermatitis 2004; 51:95.</a></li><li><a class="nounderline abstract_t">Villarreal LC, de Frutos FJ, Del Prado Sánchez Caminero M, Sebastián FV. Perineal allergic contact dermatitis due to tetracaine in a urological lubricant. Contact Dermatitis 2004; 51:321.</a></li><li><a class="nounderline abstract_t">Gallenkemper G, Rabe E, Bauer R. Contact sensitization in chronic venous insufficiency: modern wound dressings. Contact Dermatitis 1998; 38:274.</a></li><li><a class="nounderline abstract_t">Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 2008; 58:1.</a></li><li><a class="nounderline abstract_t">Schwartz HJ, Sher TH. Bisulfite sensitivity manifesting as allergy to local dental anesthesia. J Allergy Clin Immunol 1985; 75:525.</a></li><li><a class="nounderline abstract_t">Dooms-Goossens A, de Alam AG, Degreef H, Kochuyt A. Local anesthetic intolerance due to metabisulfite. Contact Dermatitis 1989; 20:124.</a></li><li><a class="nounderline abstract_t">Fisher AA. Reactions to injectable local anesthetics. Part IV: Reactions to sulfites in local anesthetics. Cutis 1989; 44:283.</a></li><li><a class="nounderline abstract_t">Goldfarb G, Simon R. Provocation of sulfite sensitive asthma (Abst). J Allergy Clin Immunol 1984; 73:135.</a></li><li><a class="nounderline abstract_t">Ivy RS. Anesthetics and methylparaben. J Am Dent Assoc 1983; 106:302.</a></li><li><a class="nounderline abstract_t">Cashman AL, Warshaw EM. Parabens: a review of epidemiology, structure, allergenicity, and hormonal properties. Dermatitis 2005; 16:57.</a></li><li><a class="nounderline abstract_t">Pratt MD, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 2001-2002 study period. Dermatitis 2004; 15:176.</a></li><li class="breakAll">www.truetest.com (Accessed on November 21, 2008).</li><li><a class="nounderline abstract_t">Condie MW, Adams RM. Influence of oral prednisone on patch-test reactions to Rhus antigen. Arch Dermatol 1973; 107:540.</a></li><li><a class="nounderline abstract_t">Kaufmann JM, Hale EK, Ashinoff RA, Cohen DE. Cutaneous lidocaine allergy confirmed by patch testing. J Drugs Dermatol 2002; 1:192.</a></li><li><a class="nounderline abstract_t">Sanchez-Morillas L, Martinez JJ, Martos MR, et al. Delayed-type hypersensitivity to mepivacaine with cross-reaction to lidocaine. Contact Dermatitis 2005; 53:352.</a></li><li><a class="nounderline abstract_t">Bircher AJ, Messmer SL, Surber C, Rufli T. Delayed-type hypersensitivity to subcutaneous lidocaine with tolerance to articaine: confirmation by in vivo and in vitro tests. Contact Dermatitis 1996; 34:387.</a></li><li><a class="nounderline abstract_t">Curley RK, Macfarlane AW, King CM. Contact sensitivity to the amide anesthetics lidocaine, prilocaine, and mepivacaine. Case report and review of the literature. Arch Dermatol 1986; 122:924.</a></li><li><a class="nounderline abstract_t">Klein CE, Gall H. Type IV allergy to amide-type local anesthetics. Contact Dermatitis 1991; 25:45.</a></li><li><a class="nounderline abstract_t">Ing Lorenzini K, Gay-Crosier Chabry F, Piguet C, Desmeules J. Meta-xylene: identification of a new antigenic entity in hypersensitivity reactions to local anesthetics. J Allergy Clin Immunol Pract 2016; 4:162.</a></li><li><a class="nounderline abstract_t">De Pasquale TMA, Buonomo A, Pucci S. Delayed-type allergy to articaine with cross-reactivity to other local anesthetics from the amide group. J Allergy Clin Immunol Pract 2018; 6:305.</a></li><li class="breakAll">www.truetest.com/PhysicianPDF/HCP8_TT_Rx_info.pdf (Accessed on November 21, 2008).</li><li><a class="nounderline abstract_t">Cuesta-Herranz J, de las Heras M, Fernández M, et al. Allergic reaction caused by local anesthetic agents belonging to the amide group. J Allergy Clin Immunol 1997; 99:427.</a></li><li><a class="nounderline abstract_t">Warrington RJ, McPhillips S. Allergic reaction to local anesthetic agents of the amide group. J Allergy Clin Immunol 1997; 100:855.</a></li><li><a class="nounderline abstract_t">Waton J, Boulanger A, Trechot PH, et al. Contact urticaria from Emla cream. Contact Dermatitis 2004; 51:284.</a></li><li><a class="nounderline abstract_t">Haugen RN, Brown CW. Case reports: type I hypersensitivity to lidocaine. J Drugs Dermatol 2007; 6:1222.</a></li><li><a class="nounderline abstract_t">Morais-Almeida M, Gaspar A, Marinho S, Rosado-Pinto J. Allergy to local anesthetics of the amide group with tolerance to procaine. Allergy 2003; 58:827.</a></li><li><a class="nounderline abstract_t">Al-Dosary K, Al-Qahtani A, Alangari A. Anaphylaxis to lidocaine with tolerance to articaine in a 12 year old girl. Saudi Pharm J 2014; 22:280.</a></li><li><a class="nounderline abstract_t">Lee J, Lee JY, Kim HJ, Seo KS. Dental anesthesia for patients with allergic reactions to lidocaine: two case reports. J Dent Anesth Pain Med 2016; 16:209.</a></li><li><a class="nounderline abstract_t">Calderon AL, Diot N, Benatir F, et al. Immediate allergic cross-reactivity to levobupivacaine and ropivacaine. Anaesthesia 2013; 68:203.</a></li><li><a class="nounderline abstract_t">Domínguez-Ortega J, Phillips-Angles E, González-Muñoz M, et al. Allergy to several local anesthetics from the amide group. J Allergy Clin Immunol Pract 2016; 4:771.</a></li><li><a class="nounderline abstract_t">Maxey-Jones CL, Palmerton A, Farmer JR, Bateman BT. Difficult Airway Management Caused by Local Anesthetic Allergy During Emergent Cesarean Delivery: A Case Report. A A Case Rep 2017; 9:84.</a></li><li><a class="nounderline abstract_t">Wieshuber C, Stoevesandt J, Trautmann A. The needle in the haystack: allergic anaphylaxis caused by the local anesthetic articaine. Eur Ann Allergy Clin Immunol 2014; 46:38.</a></li><li><a class="nounderline abstract_t">Kvisselgaard AD, Krøigaard M, Mosbech HF, Garvey LH. No cases of perioperative allergy to local anaesthetics in the Danish Anaesthesia Allergy Centre. Acta Anaesthesiol Scand 2017; 61:149.</a></li><li><a class="nounderline abstract_t">Trautmann A, Goebeler M, Stoevesandt J. Twenty Years' Experience with Anaphylaxis-Like Reactions to Local Anesthetics: Genuine Allergy is Rare. J Allergy Clin Immunol Pract 2018; 6:2051.</a></li><li><a class="nounderline abstract_t">Janas-Naze A, Osica P. The incidence of lidocaine allergy in dentists: an evaluation of 100 general dental practitioners. Int J Occup Med Environ Health 2019; 32:333.</a></li><li><a class="nounderline abstract_t">Fellinger C, Wantke F, Hemmer W, et al. The Rare Case of a Probably True IgE-Mediated Allergy to Local Anaesthetics. Case Rep Med 2013; 2013:201586.</a></li><li><a class="nounderline abstract_t">Harboe T, Guttormsen AB, Aarebrot S, et al. Suspected allergy to local anaesthetics: follow-up in 135 cases. Acta Anaesthesiol Scand 2010; 54:536.</a></li><li><a class="nounderline abstract_t">Kvisselgaard AD, Mosbech HF, Fransson S, Garvey LH. Risk of Immediate-Type Allergy to Local Anesthetics Is Overestimated-Results from 5 Years of Provocation Testing in a Danish Allergy Clinic. J Allergy Clin Immunol Pract 2018; 6:1217.</a></li><li><a class="nounderline abstract_t">Pemberton MN. Allergy to Chlorhexidine. Dent Update 2016; 43:272.</a></li><li><a class="nounderline abstract_t">Harper NJN, Cook TM, Garcez T, et al. Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6). Br J Anaesth 2018; 121:159.</a></li><li><a class="nounderline abstract_t">Lin FL, Woodmansee D, Patterson R. Near-fatal anaphylaxis to topical bacitracin ointment. J Allergy Clin Immunol 1998; 101:136.</a></li><li><a class="nounderline abstract_t">Schroer BC, Fox CC, Hauswirth DW. Skin testing after anaphylaxis to a topical Neosporin preparation. Ann Allergy Asthma Immunol 2008; 101:444.</a></li><li><a class="nounderline abstract_t">Sharif S, Goldberg B. Detection of IgE antibodies to bacitracin using a commercially available streptavidin-linked solid phase in a patient with anaphylaxis to triple antibiotic ointment. Ann Allergy Asthma Immunol 2007; 98:563.</a></li><li><a class="nounderline abstract_t">Nasser SM, Ewan PW. Opiate-sensitivity: clinical characteristics and the role of skin prick testing. Clin Exp Allergy 2001; 31:1014.</a></li><li><a class="nounderline abstract_t">Nagel JE, Fuscaldo JT, Fireman P. Paraben allergy. JAMA 1977; 237:1594.</a></li><li><a class="nounderline abstract_t">Aldrete JA, Johnson DA. Allergy to local anesthetics. JAMA 1969; 207:356.</a></li><li><a class="nounderline abstract_t">Johnson WT, DeStigter T. Hypersensitivity to procaine, tetracaine, mepivacaine, and methylparaben: report of a case. J Am Dent Assoc 1983; 106:53.</a></li><li><a class="nounderline abstract_t">Luebke NH, Walker JA. Discussion of sensitivity to preservatives in anesthetics. J Am Dent Assoc 1978; 97:656.</a></li><li><a class="nounderline abstract_t">Macy E, Schatz M, Zeiger RS. Immediate hypersensitivity to methylparaben causing false-positive results of local anesthetic skin testing or provocative dose testing. The Permanente Journal 2002; 6:17.</a></li><li><a class="nounderline abstract_t">Russo PA, Banovic T, Wiese MD, et al. Systemic allergy to EDTA in local anesthetic and radiocontrast media. J Allergy Clin Immunol Pract 2014; 2:225.</a></li><li><a class="nounderline abstract_t">Steiner UC, Gentinetta T, Hausmann O, Pichler WJ. IgE-mediated anaphylaxis to intraarticular glucocorticoid preparations. AJR Am J Roentgenol 2009; 193:W156.</a></li><li><a class="nounderline abstract_t">Calogiuri G, Garvey LH, Romita P, et al. Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations. Antiinflamm Antiallergy Agents Med Chem 2016; 15:91.</a></li><li><a class="nounderline abstract_t">Barer MR, McAllen MK. Hypersensitivity to local anaesthetics: a direct challenge test with lignocaine for definitive diagnosis. Br Med J (Clin Res Ed) 1982; 284:1229.</a></li><li><a class="nounderline abstract_t">Ravindranathan N. Allergic reaction to lignocaine. A case report. Br Dent J 1975; 138:101.</a></li><li><a class="nounderline abstract_t">Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. J Investig Allergol Clin Immunol 2011; 21:442.</a></li><li><a class="nounderline abstract_t">Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.</a></li><li><a class="nounderline abstract_t">Schatz M. Adverse reactions to local anesthetics. Immunol All Clin N Am 1992; 12:585.</a></li><li><a class="nounderline abstract_t">deShazo RD, Nelson HS. An approach to the patient with a history of local anesthetic hypersensitivity: experience with 90 patients. J Allergy Clin Immunol 1979; 63:387.</a></li><li><a class="nounderline abstract_t">Chandler MJ, Grammer LC, Patterson R. Provocative challenge with local anesthetics in patients with a prior history of reaction. J Allergy Clin Immunol 1987; 79:883.</a></li><li><a class="nounderline abstract_t">Sindel LJ, deShazo RD. Accidents resulting from local anesthetics. True or false allergy? Clin Rev Allergy 1991; 9:379.</a></li><li><a class="nounderline abstract_t">Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013; 68:702.</a></li><li><a class="nounderline abstract_t">Gall H, Kaufmann R, Kalveram CM. Adverse reactions to local anesthetics: analysis of 197 cases. J Allergy Clin Immunol 1996; 97:933.</a></li><li><a class="nounderline abstract_t">Fisher MM, Bowey CJ. Alleged allergy to local anaesthetics. Anaesth Intensive Care 1997; 25:611.</a></li><li><a class="nounderline abstract_t">Lorenzi P, Marsili M, Manetta G, et al. Prevention of anaphylactic-anaphylactoid reactions to anesthetics in high-risk allergic patients. Anesth Pain Control Dent 1993; 2:227.</a></li><li><a class="nounderline abstract_t">Troise C, Voltolini S, Minale P, et al. Management of patients at risk for adverse reactions to local anesthetics: analysis of 386 cases. J Investig Allergol Clin Immunol 1998; 8:172.</a></li><li><a class="nounderline abstract_t">Wasserfallen JB, Frei PC. Long-term evaluation of usefulness of skin and incremental challenge tests in patients with history of adverse reaction to local anesthetics. Allergy 1995; 50:162.</a></li><li><a class="nounderline abstract_t">McGarry DP, Kim YM, Casselman J, et al. Ocular desensitization in the face of local anesthetic hypersensitivity. J Allergy Clin Immunol Pract 2017; 5:819.</a></li></ol></div><div id="topicVersionRevision">Topic 2084 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8826570" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Understanding allergic reactions to local anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25380091" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lidocaine contact allergy is becoming more prevalent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6344891" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The hazards of dental local anaesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6639234" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Local dental anesthesia with epinephrine. Minimal effects on the sympathetic nervous system or on hemodynamic variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5257189" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Local anesthetic sensitivity. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12680261" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A review of paresthesia in association with administration of local anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3863856" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psychophysiological responses to dental injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18557502" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Articaine hydrochloride: a safe alternative to lignocaine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17883918" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Delayed-type hypersensitivity (type IV) reactions in dental anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840272" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Allergic contact dermatitis from lignocaine: report of 29 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17244091" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Contact dermatitis from prilocaine with cross-sensitivity to pramocaine and bupivacaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16956458" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Allergic contact dermatitis from EMLA cream in a hemodialyzed patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622627" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Delayed-type hypersensitivity to lidocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021602" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Contact allergy to lidocaine: a report of sixteen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30311217" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Differential diagnosis of late-type reactions to injected local anaesthetics: Inflammation at the injection site is the only indicator of allergic hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744414" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bacitracin: allergen of the year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2172331" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Simultaneous contact allergy to neomycin, bacitracin, and polymyxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26560642" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Contact allergy to chlorhexidine in a tertiary dermatology clinic in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15373857" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Allergic contact dermatitis from tetracaine in the beauty industry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606669" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Perineal allergic contact dermatitis due to tetracaine in a urological lubricant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9667445" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Contact sensitization in chronic venous insufficiency: modern wound dressings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158924" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3980886" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bisulfite sensitivity manifesting as allergy to local dental anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2706960" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Local anesthetic intolerance due to metabisulfite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2680302" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Reactions to injectable local anesthetics. Part IV: Reactions to sulfites in local anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Provocation of sulfite sensitive asthma (Abst)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6573405" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anesthetics and methylparaben.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16036114" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Parabens: a review of epidemiology, structure, allergenicity, and hormonal properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842061" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : North American Contact Dermatitis Group patch-test results, 2001-2002 study period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842061" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : North American Contact Dermatitis Group patch-test results, 2001-2002 study period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4266825" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Influence of oral prednisone on patch-test reactions to Rhus antigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847744" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cutaneous lidocaine allergy confirmed by patch testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364127" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Delayed-type hypersensitivity to mepivacaine with cross-reaction to lidocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879922" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Delayed-type hypersensitivity to subcutaneous lidocaine with tolerance to articaine: confirmation by in vivo and in vitro tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3740877" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Contact sensitivity to the amide anesthetics lidocaine, prilocaine, and mepivacaine. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1935033" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Type IV allergy to amide-type local anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26432515" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Meta-xylene: identification of a new antigenic entity in hypersensitivity reactions to local anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958747" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Delayed-type allergy to articaine with cross-reactivity to other local anesthetics from the amide group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958747" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Delayed-type allergy to articaine with cross-reactivity to other local anesthetics from the amide group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9058702" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Allergic reaction caused by local anesthetic agents belonging to the amide group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9438501" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Allergic reaction to local anesthetic agents of the amide group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15606654" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Contact urticaria from Emla cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18189063" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Case reports: type I hypersensitivity to lidocaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12859573" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Allergy to local anesthetics of the amide group with tolerance to procaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25067903" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Anaphylaxis to lidocaine with tolerance to articaine in a 12 year old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28884155" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dental anesthesia for patients with allergic reactions to lidocaine: two case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23121555" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Immediate allergic cross-reactivity to levobupivacaine and ropivacaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27039233" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Allergy to several local anesthetics from the amide group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448320" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Difficult Airway Management Caused by Local Anesthetic Allergy During Emergent Cesarean Delivery: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24702873" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The needle in the haystack: allergic anaphylaxis caused by the local anesthetic articaine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27878813" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : No cases of perioperative allergy to local anaesthetics in the Danish Anaesthesia Allergy Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29655774" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Twenty Years' Experience with Anaphylaxis-Like Reactions to Local Anesthetics: Genuine Allergy is Rare.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30942199" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The incidence of lidocaine allergy in dentists: an evaluation of 100 general dental practitioners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23818903" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The Rare Case of a Probably True IgE-Mediated Allergy to Local Anaesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055765" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Suspected allergy to local anaesthetics: follow-up in 135 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28988784" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Risk of Immediate-Type Allergy to Local Anesthetics Is Overestimated-Results from 5 Years of Provocation Testing in a Danish Allergy Clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27439274" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Allergy to Chlorhexidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29935567" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449517" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Near-fatal anaphylaxis to topical bacitracin ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18939736" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Skin testing after anaphylaxis to a topical Neosporin preparation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601270" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Detection of IgE antibodies to bacitracin using a commercially available streptavidin-linked solid phase in a patient with anaphylaxis to triple antibiotic ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11467991" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Opiate-sensitivity: clinical characteristics and the role of skin prick testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/576658" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Paraben allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5818162" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Allergy to local anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6574167" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypersensitivity to procaine, tetracaine, mepivacaine, and methylparaben: report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/281406" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Discussion of sensitivity to preservatives in anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Immediate hypersensitivity to methylparaben causing false-positive results of local anesthetic skin testing or provocative dose testing</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24607055" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Systemic allergy to EDTA in local anesthetic and radiocontrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620420" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : IgE-mediated anaphylaxis to intraarticular glucocorticoid preparations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27834127" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6803914" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hypersensitivity to local anaesthetics: a direct challenge test with lignocaine for definitive diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1053912" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Allergic reaction to lignocaine. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21995177" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934625" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Drug allergy: an updated practice parameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adverse reactions to local anesthetics</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/447941" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : An approach to the patient with a history of local anesthetic hypersensitivity: experience with 90 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3584743" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Provocative challenge with local anesthetics in patients with a prior history of reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1782629" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Accidents resulting from local anesthetics. True or false allergy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23617635" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8655888" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Adverse reactions to local anesthetics: analysis of 197 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9452840" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Alleged allergy to local anaesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180526" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Prevention of anaphylactic-anaphylactoid reactions to anesthetics in high-risk allergic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9684191" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Management of patients at risk for adverse reactions to local anesthetics: analysis of 386 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7604940" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Long-term evaluation of usefulness of skin and incremental challenge tests in patients with history of adverse reaction to local anesthetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838329" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Ocular desensitization in the face of local anesthetic hypersensitivity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
